From November 6, 2023 to December 31, 2023, the company has repurchased 4,057,100 shares, representing 0.28% for CNY 61.58 million. With this, the company has completed the repurchase of 4,057,100 shares, representing 0.28% for CNY 61.58 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.45 CNY | +0.63% | -0.11% | +18.95% |
05-13 | Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution | MT |
05-02 | Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.95% | 3.51B | |
+30.13% | 682B | |
+30.35% | 586B | |
-3.80% | 364B | |
+17.71% | 327B | |
+3.50% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.31% | 165B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.